CLCA2 as a Novel Immunohistochemical Marker for Differential Diagnosis of Squamous Cell Carcinoma from Adenocarcinoma of the Lung
Open Access
- 7 December 2014
- journal article
- research article
- Published by Wiley in Disease Markers
- Vol. 2014, 1-11
Abstract
Recent progress in targeted therapy for lung cancer has revealed that accurate differential diagnosis between squamous cell carcinoma (SCC) and adenocarcinoma (ADC) of the lung is essential. To identify a novel immunohistochemical marker useful for differential diagnosis between the two subtypes of lung cancer, we first selected 24 SCC-specific genes and 6 ADC-specific genes using data (case number, 980) from the Cancer Genome Atlas (TCGA) database. Among the genes, we chose theCLCA2gene, which is involved in chloride conductance and whose protein expression in lung cancer is yet to be characterized, and evaluated its protein expression status in 396 cases of primary lung cancer at Hamamatsu University Hospital. Immunohistochemical analysis revealed a significantly higher CLCA2 expression level in the SCCs than in the ADCsand also a significantly higher frequency of CLCA2 protein expression in the SCCs (104/161, 64.6%) as compared with that in the ADCs (2/235, 0.9%); sensitivity 64.6%, specificity 99.1%). The CLCA2 protein expression status was associated with the histological tumor grade in the SCCs. These results suggest that CLCA2 might be a novel excellent immunohistochemical marker for differentiating between primary SCC and primary ADC of the lung.
Keywords
This publication has 41 references indexed in Scilit:
- Combination of Napsin A and TTF-1 Immunohistochemistry Helps in Differentiating Primary Lung Adenocarcinoma From Metastatic Carcinoma in the LungApplied Immunohistochemistry & Molecular Morphology, 2011
- Utility of 10 Immunohistochemical Markers Including Novel Markers (Desmocollin-3, Glypican 3, S100A2, S100A7, and Sox-2) for Differential Diagnosis of Squamous Cell Carcinoma from Adenocarcinoma of the LungJournal of Thoracic Oncology, 2011
- Comparison of Thyroid Transcription Factor-1 Expression by 2 Monoclonal Antibodies in Pulmonary and Nonpulmonary Primary TumorsApplied Immunohistochemistry & Molecular Morphology, 2010
- hCLCA2 Is a p53-Inducible Inhibitor of Breast Cancer Cell ProliferationCancer Research, 2009
- The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III StudiesThe Oncologist, 2009
- Histological subtype of lung cancer in relation to socio-economic deprivation in South East EnglandBMC Cancer, 2008
- In situ analysis of cross-hybridisation on microarrays and the inference of expression correlationBMC Bioinformatics, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- The Putative Chloride Channel hCLCA2 Has a Single C-terminal Transmembrane SegmentJournal of Biological Chemistry, 2006
- Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non–small cell lung carcinomasHuman Pathology, 2006